Albiglutide

What it is

Albiglutide (Tanzeum/Eperzan) was a once-weekly injectable medicine used by adults with type 2 diabetes to lower blood sugar and, in a major outcomes trial, significantly cut the risk of heart attack, stroke, and cardiovascular death. Withdrawn from the US market in 2018 for commercial reasons, it remains a landmark reference agent in the GLP-1 receptor agonist class.

The scientific side

albiglutide is a once-weekly, long-acting glucagon-like peptide-1 receptor agonist consisting of two tandem copies of a modified human GLP-1 (7-36) sequence fused to recombinant human albumin. This albumin-fusion architecture extends the half-life to approximately five days by conferring resistance to degradation by dipeptidyl peptidase-4 (DPP-4) and delaying renal clearance, while the tandem GLP-1 dimer maintains full agonist activity at the GLP-1 receptor. Upon subcutaneous administration, albiglutide is primarily absorbed via the lymphatic circulation, reaching peak serum concentrations in three to five days; steady-state exposure is achieved after approximately four to five weeks of once-weekly dosing. Clearance occurs at approximately 67 mL/h with between-subject variability of 34.9%, and no covariates have been identified that require routine dose adjustment. At the pharmacodynamic level, albiglutide activates GLP-1 receptors on pancreatic beta cells to potentiate glucose-dependent insulin secretion, meaning insulin release is augmented only during hyperglycemia, substantially reducing intrinsic hypoglycemia risk. Concurrently, it suppresses inappropriate glucagon secretion from pancreatic alpha cells in a glucose-dependent fashion without impairing the counterregulatory glucagon response to hypoglycemia. Albiglutide delays gastric emptying, blunting postprandial glucose excursions, and acts on central GLP-1 receptors to promote satiety and reduce caloric intake. Its weight-loss effect is more modest than some GLP-1 receptor agonists, a finding attributed partly to limited central nervous system penetration of the large albumin-fused molecule, as supported by brain uptake pharmacokinetic data. In the pivotal HARMONY Phase III program, albiglutide 30–50 mg once weekly produced placebo-corrected reductions in glycated hemoglobin of 0.8–1.0% and fasting plasma glucose reductions of 1.3–2.4 mmol/L. In the HARMONY Outcomes cardiovascular trial involving 9,463 patients with type 2 diabetes and established cardiovascular disease, albiglutide significantly reduced the primary composite of cardiovascular death, myocardial infarction, or stroke versus placebo (HR 0.78, 95% CI 0.68–0.90, p<0.0001), demonstrating cardiovascular superiority. Unlike most GLP-1 receptor agonists, albiglutide causes gastrointestinal adverse effects at a rate only marginally greater than placebo, likely because the large molecular size of the albumin-fused construct may limit direct action on gastrointestinal receptors.

Class: GLP-1 receptor agonist — albumin-fused GLP-1 tandem dimer; long-acting incretin mimetic; antidiabetic agent

What it's studied for

• Type 2 diabetes mellitus — glycemic control (HbA1c reduction) Phase III RCT
• Cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease (HARMONY Outcomes trial) Phase III RCT
• Cardiovascular safety evaluation across the HARMONY Phase III program — prospective meta-analysis Phase III RCT meta-analysis
• Pharmacokinetics and pharmacodynamics — renal impairment and special populations Phase II RCT / PK study
• Comparative effectiveness vs. other GLP-1 receptor agonists and antidiabetic agents Mixed
• Blood-brain barrier transport and potential neurological applications (exploratory/preclinical) Animal studies only
• Albiglutide as part of GLP-1 RA class — gastric emptying and gastrointestinal physiology Human observational

Safety signals

• Injection site reactions (erythema, pain, induration)
• Pancreatitis — imbalance of cases in the HARMONY approval program
• Albiglutide-induced acute pancreatitis — case report
• Nausea, diarrhea, vomiting — gastrointestinal adverse events
• Modest HbA1c and weight loss efficacy compared with other GLP-1 receptor agonists
• Potential risk of pancreatic carcinoma — class signal for GLP-1 receptor agonists
• Hypoglycemia — low intrinsic risk but increased when combined with insulin or sulfonylureas
• No hepatotoxicity reported — absent safety signal

Community-reported dosing

No peer-reviewed studies indexed for this peptide yet.